- funded by IMI-JU
- 01 March 2011 - 31 August 2016
- 11 EFPIA members
- 10 Academia and 5 SME's
- Total cost € 23,032,609
TAKEDA as a large internationally operating pharmaceutical company targets areas where there are high unmet medical needs and their R&D experience and platform can be fully utilized, Takeda focuses their resources on the following core therapeutic areas: "Cardiovascular & Metabolic," "Oncology," "Central Nervous System," "Respiratory & Immunology," "General Medicine (Gastrointestinal & Genitourinary)" and "Vaccine." Takeda reinforces aims to provide high-quality medicines to patients worldwide.
Takeda will bring new models as well as a strong expertise in diabetes, oncology, CNS and inflammation and respiratory to the consortium. As Takeda originates in Japan, that will allow DDMoRe to make connections to Asia and could act as an ambassador with beneficial relations in that part of the globe. In addition, Takeda will bring technical expertise in modelling of discrete data, data standards and strong programming skills.